Thresholds for the value judgement of health technologies in the United Arab Emirates: a consensus approach through voting sessions

BMJ Open. 2024 Nov 4;14(11):e090344. doi: 10.1136/bmjopen-2024-090344.

Abstract

Background: In the evolving healthcare landscape of the United Arab Emirates (UAE), establishing cost-effectiveness thresholds (CETs) is pivotal to informing decision-makers about the value of health technologies.

Objective: This study aimed to establish CETs for the UAE that harmonise with international standards while reflecting the nation's unique healthcare needs and economic context.

Setting: United Arab Emirates.

Methods: A multitiered methodology was employed, involving a literature review, a panel of national experts and workshops with key stakeholders, including healthcare providers, government health departments and healthcare payers. The panel and workshops were integral in assessing global CET practices and their applicability to the UAE providing a preliminary framework for CET in the UAE. Structured voting sessions were then conducted allowing voting on crucial aspects of CET to determine the baseline threshold, multipliers for severity, rarity and health gain, and methodologies for quantifying disease severity.

Results: CETs were linked to the economic status of the UAE, with a baseline threshold of 0.75 times the gross domestic product per capita for one quality-adjusted life year gained. A multiplier system was introduced to reflect societal views on disease severity, disease rarity and the relative health benefit of health technologies. Based on the voting results, disease rarity was deemed the most crucial factor, receiving a maximum multiplier of 3X, while severity and health gain were assigned a maximum of 2X. The multiplier values for both disease severity and relative health gain would be determined on a continuous scale. The proportional or relative shortfall method would be used to assess disease severity.

Conclusions: The proposed CET framework for the UAE will be dependent on local generation of cost-effectiveness evidence. Periodic review of CETs based on initial experiences ensures the responsiveness of policymakers to the changing healthcare and economic environment.

Keywords: health economics; health equity; health policy.

MeSH terms

  • Biomedical Technology / economics
  • Consensus*
  • Cost-Benefit Analysis*
  • Health Policy
  • Humans
  • Politics
  • Quality-Adjusted Life Years
  • Technology Assessment, Biomedical / methods
  • United Arab Emirates
  • Voting